Light therapy treatment

• US 9,610,460 B2
• Filed: 08/29/2014
• Issued: 04/04/2017
• Est. Priority Date: 05/01/2009
• Status: Active Grant

• Current Assignee: Wayne State University
• Original Assignee: Wayne State University
• Inventors: Huttemann, Maik, Lee, Icksoo, Kamholz, John, Grossman, Lawrence, Przyklenk, Karin, Sanderson, Thomas
• Primary Examiner(s): VAN ROY, TOD THOMAS
• Application Number:
  US14/473,105
• Publication Number:
  US 20140371826A1
• Time in Patent Office: 949 Days
• Field of Search: 606 2, 606 3, 607 88, 607 89
• CPC Class Codes: A61B 5/145 Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissuemeasuring of blood pressure or blood flow A61B5/02; non-radiation detecting or locating of foreign bodies in blood A61B5/06
• CPC Class Codes: A61N 2005/0626 Monitoring, verifying, controlling systems and methods
• CPC Class Codes: A61N 2005/0643 Applicators, probes irradiating specific body areas in close proximity
• CPC Class Codes: A61N 2005/0652 Arrays of diodes
• CPC Class Codes: A61N 2005/0659 infrared
• CPC Class Codes: A61N 5/0613 Apparatus adapted for a specific treatment

Abstract

An exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event. Applying the light to the tissue inhibits cytochrome c oxidase activity. Another exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event and prior to either reoxygenation of the tissue or clinical intervention to reduce cell damage. An exemplary light therapy device includes at least one light source configured to generate light having a wavelength of at least one of approximately 730-770 nm, 850-890 nm, 880-920 nm, and 930-970 nm.

Claims

1. A method comprising:

identifying an ischemic event in a patient;

selecting one or more wavelength ranges, from a plurality of wavelength ranges, based on the ability of the wavelength range to inhibit cytochrome c oxidase;

generating light at the one or more selected wavelength ranges, wherein one of the selected wavelength ranges at which the light is generated includes 950 nm; and

applying the light, prior to an onset of reperfusion, to organic tissue that has experienced the ischemic event.

2. The method as set forth in claim 1, wherein the one or more wavelength ranges include wavelength ranges of:

approximately 730-770 nm;

approximately 850-890 nm;

approximately 880-920 nm; and

approximately 930-970 nm.

3. The method as set forth in claim 2, wherein the wavelength ranges include two of:

approximately 730-770 nm;

approximately 850-890 nm;

approximately 880-920 nm; and

approximately 930-970 nm.

4. The method as set forth in claim 1, wherein generating the light includes generating the light from an array of a plurality of light sources, wherein each of the plurality of light sources in the array has a power density between approximately 200 mW/cm² and 800 mW/cm².

5. The method as set forth in claim 4, further comprising reducing the generated light following the onset of reperfusion or after reperfusion is complete, wherein reducing the generated light comprises one of the steps of:

disabling one of the array of light sources individually or in a discrete group of the array of light sources; and

moving the array away from the patient.

6. The method as set forth in claim 1, wherein generating the light includes generating the light from an array of a plurality of light sources, wherein one or more of the light sources in the array has a different power density than one or more of the other light sources in the array.

7. The method as set forth in claim 1, wherein generating the light further comprises excluding a wavelength of 810 nm.

8. The method as set forth in claim 1, further comprising:

measuring oxygen saturation; and

preventing the light from being generated during the method from interfering with light used to measure the oxygen saturation.

9. The method as set forth in claim 1, further comprising applying the light to the organic tissue that has experienced the ischemic event during reperfusion of the organic tissue.

10. A method comprising:

identifying organic tissue that has experienced an ischemic event;

selecting one or more wavelength ranges based on the ability of the wavelength range to inhibit cytochrome c oxidase;

generating light having wavelength ranges of the one or more ranges that are selected from a group of ranges that includes approximately 730-770 nm, approximately 850-890 nm, approximately 880-920 nm, and approximately 930-970 nm;

excluding 810 nm from the generated light; and

applying the generated light to the organic tissue prior to an onset of reoxygenation of the organic tissue.

11. The method as set forth in claim 10, wherein the generated light has a wavelength that includes 950 nm.

12. The method as set forth in claim 10, wherein the light has more than two wavelength ranges selected from the group.

13. The method as set forth in claim 10, wherein the applying step continues for at least a time period during which the organic tissue is being reoxygenated.

14. The method as set forth in claim 10, wherein generating the light includes generating the light from an array of a plurality of light sources.

15. The method as set forth in claim 14, wherein each of the plurality of light sources in the array has a power density between approximately 200 mW/cm² and 800 mW/cm².

16. The method as set forth in claim 14, wherein one or more of the light sources in the array has a different power density than one or more of the other light sources in the array.

17. The method as set forth in claim 14, further comprising reducing the generated light following the onset of reperfusion or after reperfusion is complete, wherein reducing the generated light comprises one of the steps of:

disabling one of the light sources individually or in a discrete group of light sources; and

moving the array away from the patient.

18. The method as set forth in claim 10, further comprising:

measuring oxygen saturation; and

preventing the light from being generated during the treatment method from interfering with light used to measure the oxygen saturation.

19. The method as set forth in claim 10, further comprising applying the light to the organic tissue that has experienced the ischemic event during reoxygenation of the organic tissue.

20. A method comprising:

identifying a wavelength range based on the ability of the wavelength range to inhibit cytochrome c oxidase, the identified wavelength range from the group of ranges that includes approximately 730-770 nm, approximately 850-890 nm, approximately 880-920 nm, and approximately 930-970 nm, the identified wavelength range not from wavelength ranges that are not included in the group; and

applying the light at the identified wavelength range to organic tissue that has experienced an ischemic event, wherein application of the light is at a time prior to an onset of reoxygenation of the tissue and continues after the onset of reoxygenation of the tissue.

21. The method as set forth in claim 20, wherein the applied light has a wavelength that includes 950 nm.

22. The method of claim 20, wherein generating light comprises generating light at two or more of the wavelength ranges selected from the group.

23. The method of claim 22, wherein generating light comprises generating light at two wavelength ranges that include 750 nm and 870 nm.

24. The method of claim 22, wherein generating light comprises generating light at two wavelength ranges that include 750 nm and 950 nm.

25. The method of claim 20, further comprising excluding 810 nm from the generated light.

26. The method as set forth in claim 20, further comprising applying the light at the identified wavelength range to the organic tissue that has experienced the ischemic event during reoxygenation of the tissue.

27. A method comprising:

selecting two wavelength ranges, each of the two ranges selected based on an ability of the selected wavelength range to inhibit cytochrome c oxidase and each range selected such that, when both of the selected wavelengths are applied to an organic tissue, their combined effect reduces an amount of respiration greater than that of the individual wavelength ranges alone;

excluding at least one wavelength based on the ability of the wavelength to activate cytochrome c oxidase;

generating light simultaneously at the two selected wavelength ranges and not at the excluded wavelength, wherein the two selected wavelength ranges are selected from the group of wavelength ranges consisting of approximately 730-770 nm, approximately 850-890 nm, approximately 880-920 nm, and approximately 930-970 nm; and

applying the generated light to organic tissue that has experienced an ischemic event, wherein application of the light is initiated prior to an reoxygenation of the tissue.

28. The method as set forth in claim 27, further comprising maintaining application of the light to the tissue during at least a subset of the time period during which the tissue is being reoxygenated.

29. The method as set forth in claim 27, wherein the generated light includes 950 nm.

30. The method as set forth in claim 27, wherein the excluded wavelength is 810 nm.

31. The method as set forth in claim 27, further comprising applying the generated light to the organic tissue that has experienced the ischemic event during the reoxygenation of the tissue.

32. A method comprising:

identifying an ischemic event in a patient;

selecting one or more wavelength ranges, from a plurality of wavelength ranges, based on the ability of the wavelength range to inhibit cytochrome c oxidase;

generating light using light sources at the one or more selected wavelength ranges, wherein one of the selected wavelength ranges at which the light is generated includes 950 nm;

applying the light to organic tissue that has experienced the ischemic event;

reducing a brightness of the light following an onset of reperfusion; and

reducing the brightness by individually disabling the light sources at different times.

33. The method as set forth in claim 32, wherein applying the light to the organic tissue further comprises applying the light prior to the onset of reperfusion.

34. A method comprising:

identifying an ischemic event in a patient;

selecting one or more wavelength ranges, from a plurality of wavelength ranges, based on the ability of the wavelength range to inhibit cytochrome c oxidase;

generating light using light sources at the one or more selected wavelength ranges, wherein one of the selected wavelength ranges at which the light is generated includes 950 nm;

applying the light to organic tissue that has experienced the ischemic event;

reducing a brightness of the light following an onset of reperfusion; and

reducing the brightness by disabling discrete groups of the light sources at different times.

35. The method as set forth in claim 34, wherein applying the light to the organic tissue further comprises applying the light prior to the onset of reperfusion.